[Evaluation of danazol treatment of women with fibrocystic disease of breast].
The results of treatment of 20 female patients with fibrocystic degeneration of the breast with danazol are discussed. Diagnosis was made with the aid of mammography. Danazol was administered in the dose of 200 mg twice a day for 2 months, followed by 100 mg thrice a day, and 100 mg twice a day for further 2 months. An improvement in the clinical symptoms, decrease in LH, FSH, estradiol and progesterone levels was produced by danazol. The drug did not change LH response to LH-RH stimulation while blockade of dopaminergic receptors with metoclopramide decreased PRL response.
Baranowska
B
B
Stopińska-Głuszak
U
U
D000328:Adult; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D003613:Danazol / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D004965:Estrogen Antagonists; D005260:Female; D005348:Fibrocystic Breast Disease / Q000097:blood / Q000188:drug therapy*; D006065:Gonadotropins, Pituitary / Q000037:antagonists & inhibitors / Q000097:blood; D006801:Humans; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D011374:Progesterone / Q000037:antagonists & inhibitors / Q000097:blood; D013739:Testosterone / Q000097:blood
D004965:Estrogen Antagonists; D006065:Gonadotropins, Pituitary; D011245:Pregnadienes; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D003613:Danazol
Ocena leczenia danazolem kobiet z włóknisto-torbielkowym zwyrodnieniem sutka.